Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 2
1984 3
1985 1
1988 1
1990 1
1991 1
1992 1
1994 3
1995 3
1996 2
1997 1
1998 3
1999 3
2000 4
2001 2
2002 11
2003 4
2004 2
2005 6
2006 10
2007 6
2008 16
2009 5
2010 8
2011 7
2012 9
2013 6
2014 4
2015 12
2016 9
2017 8
2018 10
2019 17
2020 22
2021 18
2022 23
2023 30
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

256 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Showing results for olivera cancer
Search for Olivera Čančar instead (1 results)
IL8, Neutrophils, and NETs in a Collusion against Cancer Immunity and Immunotherapy.
Teijeira A, Garasa S, Ochoa MC, Villalba M, Olivera I, Cirella A, Eguren-Santamaria I, Berraondo P, Schalper KA, de Andrea CE, Sanmamed MF, Melero I. Teijeira A, et al. Clin Cancer Res. 2021 May 1;27(9):2383-2393. doi: 10.1158/1078-0432.CCR-20-1319. Epub 2020 Dec 29. Clin Cancer Res. 2021. PMID: 33376096 Review.
A cancer permissive immune microenvironment is present in a large proportion of the patients with cancer who do not respond to immunotherapy approaches intended to trigger preexisting antitumor immune responses, for instance, immune checkpoint blockade. ...IL8 has b …
A cancer permissive immune microenvironment is present in a large proportion of the patients with cancer who do not respond to …
Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers.
Teijeira A, Migueliz I, Garasa S, Karanikas V, Luri C, Cirella A, Olivera I, Cañamero M, Alvarez M, Ochoa MC, Rouzaut A, Rodriguez-Ruiz ME, Sanmamed MF, Klein C, Umaña P, Ponz M, Bacac M, Melero I. Teijeira A, et al. Theranostics. 2022 Jan 1;12(3):1373-1387. doi: 10.7150/thno.63359. eCollection 2022. Theranostics. 2022. PMID: 35154495 Free PMC article.
Here we study its performance against three-dimensional tumor organoids in cocultures with T cells as compared to a higher affinity CEACAM5-CD3 (CEACAM5-TCB) bispecific antibody using time-lapse confocal microscopy. Methods: Pre-labelled spheroids derived from colon cancer
Here we study its performance against three-dimensional tumor organoids in cocultures with T cells as compared to a higher affinity CEACAM5- …
SARS-CoV-2 infection and persistence in the human body and brain at autopsy.
Stein SR, Ramelli SC, Grazioli A, Chung JY, Singh M, Yinda CK, Winkler CW, Sun J, Dickey JM, Ylaya K, Ko SH, Platt AP, Burbelo PD, Quezado M, Pittaluga S, Purcell M, Munster VJ, Belinky F, Ramos-Benitez MJ, Boritz EA, Lach IA, Herr DL, Rabin J, Saharia KK, Madathil RJ, Tabatabai A, Soherwardi S, McCurdy MT; NIH COVID-19 Autopsy Consortium; Peterson KE, Cohen JI, de Wit E, Vannella KM, Hewitt SM, Kleiner DE, Chertow DS. Stein SR, et al. Nature. 2022 Dec;612(7941):758-763. doi: 10.1038/s41586-022-05542-y. Epub 2022 Dec 14. Nature. 2022. PMID: 36517603 Free PMC article.
Lung Cancer in Peru.
Ruiz R, Galvez-Nino M, Poquioma E, Limache-García A, Amorin E, Olivera M, Valdiviezo N, Trejo JM, Heredia A, Sarria G, Aguilar A, Raez L, Neciosup SP, Gomez HL, Payet E, Mas L. Ruiz R, et al. J Thorac Oncol. 2020 Jun;15(6):891-898. doi: 10.1016/j.jtho.2020.01.018. J Thorac Oncol. 2020. PMID: 32471564 Free article. No abstract available.
Novel strategies exploiting interleukin-12 in cancer immunotherapy.
Cirella A, Luri-Rey C, Di Trani CA, Teijeira A, Olivera I, Bolaños E, Castañón E, Palencia B, Brocco D, Fernández-Sendin M, Aranda F, Berraondo P, Melero I. Cirella A, et al. Pharmacol Ther. 2022 Nov;239:108189. doi: 10.1016/j.pharmthera.2022.108189. Epub 2022 Apr 14. Pharmacol Ther. 2022. PMID: 35430292 Review.
Clinical Cancer Genetics Disparities among Latinos.
Cruz-Correa M, Pérez-Mayoral J, Dutil J, Echenique M, Mosquera R, Rivera-Román K, Umpierre S, Rodriguez-Quilichini S, Gonzalez-Pons M, Olivera MI, Pardo S; Puerto Rico Clinical Cancer Genetics Consortia. Cruz-Correa M, et al. J Genet Couns. 2017 Jun;26(3):379-386. doi: 10.1007/s10897-016-0051-x. Epub 2016 Dec 12. J Genet Couns. 2017. PMID: 27957667 Free PMC article. Review.
The three major hereditary cancer syndromes in Latinos (Hereditary Breast and Ovarian Cancer, Familial Adenomatous Polyposis and Lynch Syndrome) have been shown to exhibit geographic disparities by country of origin suggesting admixture-based disparities. A solid in …
The three major hereditary cancer syndromes in Latinos (Hereditary Breast and Ovarian Cancer, Familial Adenomatous Polyposis a …
GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19.
Pairo-Castineira E, Rawlik K, Bretherick AD, Qi T, Wu Y, Nassiri I, McConkey GA, Zechner M, Klaric L, Griffiths F, Oosthuyzen W, Kousathanas A, Richmond A, Millar J, Russell CD, Malinauskas T, Thwaites R, Morrice K, Keating S, Maslove D, Nichol A, Semple MG, Knight J, Shankar-Hari M, Summers C, Hinds C, Horby P, Ling L, McAuley D, Montgomery H, Openshaw PJM, Begg C, Walsh T, Tenesa A, Flores C, Riancho JA, Rojas-Martinez A, Lapunzina P; GenOMICC Investigators; SCOURGE Consortium; ISARICC Investigators; 23andMe COVID-19 Team; Yang J, Ponting CP, Wilson JF, Vitart V, Abedalthagafi M, Luchessi AD, Parra EJ, Cruz R, Carracedo A, Fawkes A, Murphy L, Rowan K, Pereira AC, Law A, Fairfax B, Hendry SC, Baillie JK. Pairo-Castineira E, et al. Nature. 2023 May;617(7962):764-768. doi: 10.1038/s41586-023-06034-3. Epub 2023 May 17. Nature. 2023. PMID: 37198478 Free PMC article.
Interleukin-18 in cancer immunology and immunotherapy.
Cirella A, Olivera I, Luri-Rey C, Bolaños E, Berraondo P, Melero I. Cirella A, et al. Expert Opin Ther Targets. 2023 Jul-Dec;27(11):1035-1042. doi: 10.1080/14728222.2023.2287574. Epub 2023 Dec 7. Expert Opin Ther Targets. 2023. PMID: 37993172
INTRODUCTION: Interleukin-18 (IL-18) is a myeloid leukocyte inflammatory mediator whose main known function is to elicit IFNgamma secretion from T and NK cells. AREAS COVERED: This function offers potential in cancer immunotherapy but as a single treatment, preclinical and …
INTRODUCTION: Interleukin-18 (IL-18) is a myeloid leukocyte inflammatory mediator whose main known function is to elicit IFNgamma secretion …
Hereditary cancer syndromes in Latino populations: genetic characterization and surveillance guidelines.
Cruz-Correa M, Pérez-Mayoral J, Dutil J, Echenique M, Mosquera R, Rivera-Román K, Umpierre S, Rodriguez-Quilichini S, Gonzalez-Pons M, Olivera MI, Pardo S; Puerto Rico Clinical Cancer Genetics Consortia. Cruz-Correa M, et al. Hered Cancer Clin Pract. 2017 Jan 21;15:3. doi: 10.1186/s13053-017-0063-z. eCollection 2017. Hered Cancer Clin Pract. 2017. PMID: 28127413 Free PMC article. Review.
Hereditary cancer predisposition syndromes comprise approximately 10% of diagnosed cancers; however, familial forms are believed to account for up to 30% of some cancers. ...Although the incidence of hereditary cancers is low, patients diagnosed with h …
Hereditary cancer predisposition syndromes comprise approximately 10% of diagnosed cancers; however, familial forms are believ …
Advances in mRNA-based drug discovery in cancer immunotherapy.
Di Trani CA, Fernandez-Sendin M, Cirella A, Segués A, Olivera I, Bolaños E, Melero I, Berraondo P. Di Trani CA, et al. Expert Opin Drug Discov. 2022 Jan;17(1):41-53. doi: 10.1080/17460441.2021.1978972. Epub 2021 Sep 20. Expert Opin Drug Discov. 2022. PMID: 34496689 Review.
INTRODUCTION: Immune checkpoint inhibitors and adoptive T-cell therapy based on chimeric antigen receptors are the spearhead strategies to exploit the immune system to fight cancer. To take advantage of the full potential of the immune system, cancer immunotherapy m …
INTRODUCTION: Immune checkpoint inhibitors and adoptive T-cell therapy based on chimeric antigen receptors are the spearhead strategies to e …
256 results